Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
Sign Up to like & getrecommendations! Published in 2018 at "Metabolism: clinical and experimental"
DOI: 10.1016/j.metabol.2018.03.009
Abstract: AIMS We explored the risks associated with metformin plus sulfonylurea (MET + SU) or MET plus a dipeptidyl peptidase-4 inhibitor (MET + DPP4i) for hypoglycemia, cardiovascular disease (CVD) events and all-cause mortality in type 2 diabetes (T2D) patients with… read more here.
Keywords: events cause; metformin combined; cause mortality; cvd events ... See more keywords